

DAFTAR PUSTAKA

1. Sukrisman, Lugyanti. Trombosis vena dalam dan emboli paru. Buku ajar ilmu penyakit dalam Fakultas Kedokteran UI. Jakarta: FKUI. 2016: 2820—4.
2. Setiabudy RD. Patofisiologi trombosis. Dalam: Setiabudy RD, ed. Hemostasis dan trombosis. Jakarta: FKUI. 2007; 34—47.
3. Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous Thromboembolism : A Public Health Concern. *Am J Prev Med.* 2010; 38(4S): S495—S501.
4. Wakefield TW, Myers DD, Henke PK. Mechanisms of Venous Thrombosis and Resolution. *Arterioscler Thromb Vasc Biol.* 2008; 387—90.
5. White RH, Keenan CR. Effect of race and ethnicity on the incidence of venous thromboembolism. *Thrombosis research.* 2009; 123(4): 511—7.
6. Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, et al. Venous thromboembolism (VTE) in Europe : The number of VTE events and associated morbidity and mortality. *Thromb Haemost.* 2007; 98: 756—64.
7. Streiff MB. Prevention and treatment of venous thromboembolism. *Hematol Educ Program.* 2014; 16: 273—91.
8. Hollenhorst MA, Battinelli EM. Thrombosis, Hypercoagulable States, and Anticoagulants. *Prim Care Clin Office Pract.* 2016; 43: 619—635.
9. Welch Ellen. Venous thromboembolism : a nurse guide to prevention and management. Wiley-Blackwell. 2010: 41—8.
10. Anderson FA, and Spencer FA. Risk Factors for Venous Thromboembolism. *Circulation.* 2003: I9—I14.
11. Levi M, Poll T. The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients. *Seminars in thrombosis and homeostasis.* 2008; 34(5): 459—68.
12. Levi M, Poll T. Two-way interaction between inflammation and coagulation. *TCM.* 2005; 15(7): 254—9.
13. Hoppensteadt D, Williams M, Syed D, Guler N, Mosier M, Fareed J. Baseline thrombin generation markers and functional antithrombin levels in sepsis

associated coagulopathies are predictive of the severity of pathogenesis. *Blood journal*. 2015; 1—3.

14. Lippi G, Cervellin G, Franchini M, Favaloro EJ. Biochemical markers for the diagnosis of venous thromboembolism: the past, present and future. *J Thromb Thrombolysis*. 2010; 30: 459—71.
15. Sukorini U, Mulyono B, Sutaryo, Riyanto B. 2016. Faktor Risiko Prethrombotic State dan Indeks Trombosis pada Trombosis Vena Dalam [tesis]. Yogyakarta : Universitas Gajah Mada.
16. Wexel F, Dahl O, Docmedsci, Pripp A, Seljeflot I. Thrombin generation in patients with suspected venous thromboemboli. *Clin and Appl Thromb/Hemos*. 2017; 23(5): 416—21.
17. Djumhana AT, Tambunan KL, Sukrisman L, Effendi S, Rachman A, Setiawati A, et al. Underutilization of Anticoagulant for Venous Thromboembolism Prophylaxis in Three Hospitals in Jakarta. *The Indonesian Journal of Internal Medicine*. 2015; 47(2): 136—45.
18. Suciadi LP, Dinarti LK. Prevention of Venous Thrombo-Embolicism in Non-Surgical Hospitalized Patients. *Med J Indones*. 2010; 19(1): 71—7.
19. Streiff MB, Lau BD. Thromboprophylaxis in nonsurgical patients. *Hematol Educ Program*. 2012: 631—7.
20. Streiff MB, Lau BD. Thromboprophylaxis in nonsurgical patients. *Hematol Educ Program*. 2012: 631—7.
21. Hull RD. Relevance of Immobility and Importance of Risk Assessment Management for Medically Ill Patients. *Clinical and Applied Thrombosis/Hemostasis*. 2012; 19(3): 268—76.
22. Wang TW, Wong CA, Milligan PE, Thoenke MS, Woeltje KF, Gage BF. Risk factors for inpatient venous thromboembolism despite thromboprophylaxis. *Thromb Res*. 2014; 133: 25—9.
23. Khan SR, Lim W, Dunn AS, Cushman S, Dentali F, Akl EA, et al. Prevention of VTE in non surgical patients. Antithrombotic therapy and prevention of thrombosis, 9th ed : American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. 2012; 141(2): e195S—226S.

24. Pangalila JF. Konsensus Penatalaksanaan Tromboemboli Vena (TEV) pada Penyakit Kritis. Perhimpunan Dokter Intensive Care Indonesia. 2019.
25. Zenahlikova Z, Kvasnicka J, Kudrnova Z, Magda S, Brzezкова R, Mazoch J, et al. FXa inhibitor and coagulation changes during DVT prophylaxis by enoxaparin over the course of a 15-day follow-up in septic patients. *Clin Appl Thromb Hemost*. 2010; 16(5): 584—90.
26. Peternel P, Terbizan M, Tratar G. Marker of hemostatic system activation during treatment of deep vein thrombosis with subcutaneous unfractionated or low-molecular weight heparin. *Thromb Res*. 2002 ; 105(3): 241—6.
27. Traby L, Kaider A, Schmid R, Kranz A, Quehenberger P, Kyrle PA, et al. The effects of low-molecular-weight heparin at two different dosages on thrombin generation in cancer patients. *Thromb and Haemost*. 2010; 104(1): 92—9.
28. Cohen AT, Zaw HM, Alikhan R. Benefits of deep-vein thrombosis prophylaxis in the nonsurgical patient : The MEDENOX trial. *Semin Hematol*. 2001; 38(2 suppl5): 31—8.
29. Tun NM, Thein HO. Prevention and treatment of venous thromboembolism with new oral anticoagulants : a practical update for clinician. *Hindawi pub corp thromb*. 2013; 1836s16: 1—10.
30. Bhalla V, Abdel-Latif A, Bhalla M, Ziada K, Williams MV, Smyth SS. Meta-analysis comparing the efficacy, safety, and cost-benefit of direct oral anticoagulants versus enoxaparin thromboprophylaxis to prevent venous thromboembolism among hospitalized patients. *The Am J of Cardio*. 2018: 1236—43.
31. Perhimpunan Thrombosis Hemostasis Indonesia (PTHI). Panduan nasional tromboemboli vena. 2018.
32. Cohen AT, Spiro TE, Bu'ller HR, Haskell L, Hu D, Hull R, et al. Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients. *N engl j med*. 2013; 368(6): 513—22.
33. Goodnight SH, Hathaway WE. Mechanisms of hemostasis and thrombosis. *J Thromb Haemost*. 2001: 3—16.

34. Mackman N. New insight into the mechanism of venous thrombosis. *J clin invest.* 2012; 122: 2331—6.
35. Esmon CT. Basic mechanism and pathogenesis of venous thrombosis. *Blood.* 2009; 23: 225—9.
36. Levi M, Tymen T, Keller, van Gorp E, Ten Cate H. Infection and inflammation and the coagulation system. *Jour Cardio Res.* 2003: 26—39.
37. Merli GJ. Pathophysiology of venous thrombosis, thrombophilia, and the diagnosis of deep vein thrombosis-pulmonary embolism in the elderly. *Clin Geriatr Med.* 2006; 22: 75—92.
38. Huisman MV, Barco S, Cannegieter SC, Le Gal G, Konstantinides SV, Reitsma PH, et al. Pulmonary embolism. *Primer.* 2018; 4: 1—14.
39. Baglin TP, White K, Charles A. Fatal pulmonary embolism in hospitalised medical patients. *J Clin Pathol.* 1997; 50: 609—10.
40. Clinical practice guideline for the prevention of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to Australian hospitals. N.H.a.M.R. Melbourne. 2009.
41. Centers for Disease Control and Prevention (CDC). Venous thromboembolism in adult hospitalizations—United States, 2007–2009. *MMWR Morb Mortal Wkly Rep.* 2012; 61: 401—4.
42. Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors. *J Thromb Haemost.* 2005; 3: 1611—17.
43. Franchini M and Mannucci PM. Direct oral anticoagulants and venous thromboembolism. *Eur Respir Rev.* 2016; 25: 295—302.
44. Kroegel C, Reissig A. Principle Mechanisms Underlying Venous Thromboembolism: Epidemiology, Risk Factors, Pathophysiology and Pathogenesis. *Resp.* 2003; 70: 7—30.
45. Saghazadeh A, Rezaei N. Inflammation as a cause of venous thromboembolism. *Crit rev in onco/ hematol.* 2016: 1—14.
46. Khalil J, Bensaid B, Elkacemi H, Afif M, Younes B, Kebdani T, et al. Venous thromboembolism in cancer patients: an underestimated major health problem. *World jour of surg onco.* 2015; 13: 1—17.

47. Andrew DB, Simon D. Arterial and venous thrombosis in cancer patients. *Cardio res and pract.* 2011; 1—11.
48. Heit JA. Epidemiology of venous thromboembolism. *Nat Rev Cardiol.* 2015; 12(8): 464—74.
49. Mari D, Mannucci PM, Coppola R, et al. Hypercoagulability in centenarians: the paradox of successful aging. *Blood.* 1995; 85(11): 3144—9.
50. Schmidt M, Horvath-Puho E, Thomsen RW, Smeeth L, Sorensen HT. Acute infections and venous thromboembolism. *J of Int Med.* 2011; 608—18.
51. Lee JJ, Pope JE. A meta-analysis of the risk of the venous thromboembolism in inflammatory rheumatic disease. *Arthritis Res and Ther.* 2014; 16(435): 1—8.
52. Ota S, Wada H, Abe Y, Yamada E, Sakaguchi A, Nishioka J, Hatada T. Elevated levels of prothrombin fragment 1+2 indicate high risk of thrombosis. *Clin and appl thromb/hemost.* 2008; 1—7.
53. Carman TL. Biomarkers in the Management of Venous Thromboembolism. *Biomarkers in Cardiovascular Disease.* 2019; 14: 149—58.
54. Jespersen J, Bertina RM, Haverkate F. Laboratory technique in thrombosis : a manual. 2nd ed. Leiden. Springer. 1999: 199—217.
55. Jacobs B, Obi A, Wakefield T, Arbor A, Mich. Diagnostic biomarkers in venous thromboembolic disease. *Jour of vasc surg.* 2016: 1—8.
56. Rocha AT, Paiva EF, Lichtenstein A, milani R, filho CC, Maffei FH . Risk-assessment algorithm and recommendations for venous thromboembolism prophylaxis in medical patients. *Vasc Health and Risk Manag.* 2007; 3(4): 533—53.
57. Schunemann HJ, Cushman M, Burnett AE, Kahn SR, Beyer-Westendorf J, Spencer FA, Rezende SM, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. *The American Society of Hematology.* 2018: 1—21.
58. Clark BM, d'Ancona G, Kinirons M, Hunt BJ, Hopper A. Effective quality improvement of thromboprophylaxis in acute medicine. *BMJ Qual Saf.* 2011; 20: 460—4.

59. Zhou H, Hu Y, Li X, Wang L, Wang M, Xiao J, et al. Assessment of the Risk of Venous Thromboembolism in Medical Inpatients using the Padua Prediction Score and Caprini Risk Assessment Model. *J Atheroscler Thromb*. 2018; 25: 1091—104.
60. Blondon M, Spirk D, Kucher N, Aujesky D, Hayoz D, Beer JH, et al. Comparative Performance of Clinical Risk Assessment Models for Hospital-Acquired Venous Thromboembolism in Medical Patients. *Throm and Haemost*. 2018; 118(1): 82—88.
61. Cruden P, Cushman M, Repp AB. Hospitalist assessment of venous thromboembolism and bleeding risk: A survey study. *Thromb Res*. 2019: 4—12.
62. Thrombosis Guidelines Group. Prevention of venous thromboembolism in acutely ill hospitalized medical patients. Thrombosis Guidelines Group of the Belgian Society on Thrombosis and Haemostasis and the Belgian Working Group on Angiology. 2019: 1—2.
63. Agrawal YK, Vaidya H, Bhatt H, Manna K, Brahmshatriya P. Recent advances in the treatment of thromboembolic diseases : venous thromboembolism. *Wiley InterScience*. 2007; 27(6): 891—914.
64. Hirsh J. Heparin and Low Molecular Weight Heparin. *BR J Hematol*. 2015. 1—8.
65. Harter K, Levine M, Henderson S. Anticoagulation drug therapy : a review. *West j of emerg med*. 2015; 16(1): 11—18.
66. Alquwaizani M, Buckley L, Adma C, Fanikos J. Anticoagulants : a review of the pharmacology, dosing, and complication. *Curr emerg hosp med rep*. 2013; 1: 83—97.
67. Connors JM. Testing and monitoring direct oral anticoagulants. *Blood*. 2018; 132(19): 2009—13.
68. Schwarb H and Dimitrios A. Tsakiris. New Direct Oral Anticoagulants (DOAC) and Their Use Today. *Dent J*. 2016; 4(5): 1—11.
69. Knotts T, Mousa SA. Anticoagulation in Venous Thromboembolism Prophylaxis in Medically Ill Patients: Potential Impact of NOACs. *Am J of Cardio Drugs*. 2019: 1—12.

70. Medicines Management and Therapeutics Committee. Treatment of venous thromboembolism (VTE) with apixaban or rivaroxaban in adults. *Oxf Univ Hosp*. 2018: 1—4.
71. Yeh CH, Hogg K, Weitz JI. Overview of the new oral anticoagulants opportunities and challenges. *Arterioscler Thromb Vasc Biol*. 2015: 1056—64.
72. Tambunan KL, Kurnianda J, Suharti C, Wardhani SO, Sukrisman L, Sutandyo N, et al. IDENTIA Registry : incidence of deep vein thrombosis in medically ill subject at high risk in Indonesia : a prospective study. *Acta Med Indones-Indones J Intern Med*. 2020; 52(1): 14—24.
73. Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM, et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. *N Eng J Med*. 2011; 365(23): 2167—77.
74. Cohen AT, Harrington RA, Goldhaber SZ, Hull RD. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. *N Engl J Med*. 2016; 375: 534—44.
75. Baglin T, Luddington R, Brown K, Baglin C. High risk of recurrent venous thromboembolism in men. *J Thromb Haemost*. 2004; 2: 2152—5.
76. Roach REJ, Cannegieter SC, Lifjering WM. Differential risks in men and women for first and recurrent venous thrombosis : the role of genes and environment. *J Thromb Haemost*. 2014; 12: 1593—1600.
77. Ay L, Kopp HP, Brix JM, Ay C, Quehenberg P, Schernthaner GH, et al. Thrombin generation in morbid obesity : significant reduction after weight loss. *J Thromb Haemost*. 2010; 8: 759—65.
78. Pottier P, Hardouin JB, Lejeune S, Jolliet P, Gillet B, and Planchon B. Immobilization and the risk of venous thromboembolism. A meta-analysis on epidemiological studies. *Thromb Res*. 2009; 124: 468—76.
79. Gouya G, Palkovits S, Kapiotis S, Madl C, Locker G, Stella A, et al. Bioactivity of enoxaparin in critically ill patients with normal renal function. *Brit jour of clin pharm*. 2012; 74(5): 806—14.
80. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. *Lancet Oncol*. 2005; 6: 401—10.

81. Marek ZW, Rucinska M, Zimnoch L, Jaromin J, Piotrowski Z, Malgorzata R, et al. Expression of prothrombin fragment 1+2 in cancer tissue as an indicator of local activation of blood coagulation. *Thromb Res.* 2000; 97: 335—42.
82. Zhu R, Hu Y, Tang L. Reduced cardiac function and risk of venous thromboembolism in Asian countries. *Thromb jour.* 2017; 15(12): 1—8.
83. Barbar S, Noventa F, Rossetto V, Ferari A, Brandolin B, Perlati M, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism : the padua prediction score. *J Thromb Hemost.* 2010; 8(11): 2450—7.
84. Fardila F. 2019. Pengaruh pemberian low molecular weight heparin terhadap kadar prothrombin fragment 1+2 pada pasien community acquired pneumonia dengan sepsis [skripsi]. Padang : Universitas Andalas.
85. Kawai Y, Fuji T, Fujita S, Kimura T, Ibusuki K, Abe K, et al. Edoxaban versus enoxaparin for prevention for the prevention of venous thromboembolism after total knee or hip arthroplasty : pooled analysis of coagulation biomarkers and primary efficacy and safety endpoints from two phase 3 trials. *Thromb Jour.* 2016; 14(48): 1—8.
86. Gheorgiade M, Thyssen A, Zolynas R, Nadar VK, Greenberg BH, Mehra M, et al. Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarker of hypercoagulability in patients with chronic heart failure. *The journal of heart and lung transpl.* 2011; 30(2): 218—26.

